Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time

NCT01755546 is registered in ClinicalTrials.gov with BioDelivery Sciences International as lead sponsor.

NCT NCT01755546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01755546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time
Lead sponsor
BioDelivery Sciences International
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2012
Completion date
November 30, 2014
Enrollment
304 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

low back pain, neuropathic pain, osteoarthritis